logo

For the Inventor, By the Inventor

Wilmington, DE, United States of America

Glaxosmithkline LLC


USPTO Granted Patents = 358

% Expired Patents = 52.5



Trademarks = 113

Forward Citations = 2,600

Loading Chart...
Loading Chart...

660 inventors (with patents filed for the assignee):

goldMedal Diane Mary Coe (18 out of 40 patents)

silverMedal Stephen Allan Smith (17 out of 42 patents)

bronzeMedal William Henry Miller (15 out of 73 patents)

4.  Steven David Knight (15 out of 50 patents)

5.  Mui Cheung (13 out of 43 patents)

6.  Ralph A Rivero (13 out of 14 patents)

7.  Rosanna Tedesco (12 out of 12 patents)

8.  Snigdha Mishra (12 out of 12 patents)

9.  Meagan B Rouse (12 out of 18 patents)

10.  Gustav R Fenton (12 out of 15 patents)

11.  Xinrong Tian (11 out of 15 patents)

12.  Junya Qu (10 out of 11 patents)

13.  Emmanuel Hubert Demont (10 out of 23 patents)

14.  Neil W Johnson (10 out of 20 patents)

15.  Jeffrey S Brunner (10 out of 10 patents)


Core Competencies:
Pharmaceutical Compositions
Prolyl Hydroxylase Inhibitors
Myelofibrosis Treatment
Eosinophilic Bronchitis
Sirtuin Modulators
PI3 Kinase Inhibitors
Diacylglycerol Acyltransferase Inhibitors
Bromodomain Inhibitors
Pyrazolopyrimidine Compounds
Indoles
HIV Treatment
Omega-3 Fatty Acids

358 patents:

1. 12576089 - Platelet count-agnostic methods of treating myelofibrosis (2026-03-17),
2. 12570614 - Phenyl Amino Pyrimidine Compounds and Uses Thereof (2026-03-10),
3. RE50497 - (N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide (2025-07-22),
4. D1042109 - Package (2024-09-17),
5. 11963962 - Platelet count-agnostic methods of treating myelofibrosis (2024-04-23),
6. 11643397 - Prolyl hydroxylase inhibitors (2023-05-09),
7. 11390671 - Biopharmaceutical compositions and methods for pediatric patients (2022-07-19),
8. 11325972 - Methods of treatment of eosinophilic bronchitis with an anti-IL-5 antibody (2022-05-10),
9. D920093 - Package (2021-05-25),
10. 10745449 - UspA2 protein constructs and uses thereof (2020-08-18),
11. 10660898 - Benzimidazole derivatives as PI3 kinase inhibitors (2020-05-26),
12. 10590135 - Substituted bridged urea analogs as sirtuin modulators (2020-03-17),
13. 10478426 - Enhancer of Zeste Homolog 2 inhibitors (2019-11-19),
14. 10392625 - Host cells and methods of use (2019-08-27),
15. 10391717 - Package and heat sealing device (2019-08-27),
Company Overview
GlaxoSmithKline LLC, headquartered in Wilmington, DE, is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of innovative therapeutic solutions. The company specializes in a range of pharmaceutical compositions, with notable expertise in prolyl hydroxylase inhibitors and treatments for conditions such as myelofibrosis and eosinophilic bronchitis. GSK is also engaged in advancing research in sirtuin modulators, PI3 kinase inhibitors, diacylglycerol acyltransferase inhibitors, and bromodomain inhibitors, contributing significantly to the evolving landscape of modern medicine.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

Glaxosmithkline LLC USPTO Patent Assignee Logo
358 Patents

#21 in Wilmington, DE

#27 in Delaware

#1,274 in US

#2,564 in the World

Wilmington, DE (US)
Wilmington, DE, United States of America

Glaxosmithkline LLC

Forward Citations = 2,600

660 inventors:

goldMedal Diane Mary Coe (18 out of 40 patents)

silverMedal Stephen Allan Smith (17 out of 42 patents)

bronzeMedal William Henry Miller (15 out of 73 patents)

4.  Steven David Knight (15 out of 50 patents)

5.  Mui Cheung (13 out of 43 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Glaxosmithkline LLC. Retrieved from https://idiyas.com/company/glaxosmithkline

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…